Stockreport

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy [Yahoo! Finance]

Palatin Technologies, Inc.  (PTN) 
NASDAQ:AMEX Investor Relations: palatin.com/investors/overview
PDF Demonstrated efficacy at 6 months 71% percent of patients achieved a 30% reduction in the urine protein to creatinine ratio (UP/Cr) 71% of patients achieved improve [Read more]